Goldline Pharmaceutical Limited (BOM:544759)
India · Delayed Price · Currency is INR 38.84
-1.55 (-3.84%)
At close: Jul 14, 2026
Goldline Pharmaceutical Revenue
In the fiscal year ending March 31, 2026, Goldline Pharmaceutical had annual revenue of 311.99M INR with 11.20% growth. Goldline Pharmaceutical had revenue of 97.93M in the quarter ending March 31, 2026.
Revenue
311.99M
Revenue Growth
+11.20%
P/S Ratio
1.20
Revenue / Employee
n/a
Employees
n/a
Market Cap
372.86M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 311.99M | 31.43M | 11.20% |
| Mar 31, 2025 | 280.56M | 44.90M | 19.05% |
| Mar 31, 2024 | 235.66M | 37.18M | 18.73% |
| Mar 31, 2023 | 198.48M | -41.62M | -17.33% |
| Mar 31, 2022 | 240.11M | 21.15M | 9.66% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Centuple Global | 5.74B |
| Novelix Pharmaceuticals | 1.32B |
| Dipna Pharmachem | 1.29B |
| Chandra Bhagat Pharma | 1.16B |
| VijayPD Ceutical | 1.04B |
| Medico Intercontinental | 853.55M |
| Medistep Healthcare | 708.31M |
| Constronics Infra | 486.14M |